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Chlorambucil versus observation after anti-Helicobacter therapy
in gastric MALT lymphomas: results of the international
randomised LY03 trial
Summary
Gastric mucosa-associated lymphoid tissue (MALT) lymphomas are
uncommon tumours characterised by a tendency to remain localised for
long periods. The aetiological association between MALT lymphomas and
Helicobacter pylori is well established. The role of additional chemotherapy
after H. pylori eradication in localised MALT lymphomas is unclear. The
LY03 trial was designed to establish whether chlorambucil after treatment for
H. pylori would help prevent recurrence. Patients were treated with
antibiotics for H. pylori infection. Those with successful eradication of
H. pylori and no evidence of progression of lymphoma were eligible for
randomisation to chlorambucil or observation. Two hundred and thirty-one
patients were registered. Ninety-seven percent patients had H. pylori
eradicated after antibiotics and 59% achieved macroscopically normal
gastric mucosa. One hundred and ten patients were randomised. With a
median follow-up of 58 months, six patients were dead and 17 had recurrent/
progressive disease. The recurrence/progression rates at 5 years were 11% for
chlorambucil, and 21% for observation with a difference of 10%, 95%
conﬁdence interval (CI) = )9% to 29%, P =0 Æ15. No difference was detected
in recurrence/progression-free survival [Hazard Ratio (HR) = 0Æ96, 95%
CI = 0Æ41–2Æ2, P =0 Æ91] or overall survival (HR = 1Æ93, 95% CI = 0Æ39–9Æ58,
P =0 Æ42). This is the ﬁrst randomised trial to show there is no good evidence
to support that additional single agent chemotherapy to anti-H. pylori
treatment contributes to prevent recurrence in localised gastric MALT
lymphomas.
Keywords: gastric MALT lymphomas, chemotherapy, randomised controlled
trial, chlorambucil, observation.
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Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 144, 367–375 doi:10.1111/j.1365-2141.2008.07486.xAbout 40% of all gastric lymphomas (Koch et al, 2005) are
indolent and the majority of these are extranodal marginal
zone B cell of mucosa-associated lymphoid tissue (MALT) type
(Isaacson & Spencer, 1987). MALT lymphomas account for
approximately 8% of B-cell lymphomas and are characterised
by an indolent natural history and a tendency to remain
localised for long periods of time.
The onset of MALT lymphoma in the stomach is usually
preceded by Helicobater pylori infection and this organism can
be found in the gastric mucosa in over 90% of cases
(Wotherspoon et al, 1991). At the time the study was designed
an endoscopic diagnosis of chronic gastritis had often been
made before the diagnosis was made histologically. Many
patients diagnosed as gastric MALT lymphomas underwent
gastrectomy as the primary treatment. For localised low-grade
lymphoma conﬁned to the stomach wall, the prognosis was
excellent with over 90% of patients surviving 5 years after
resection (Ferrucci & Zucca, 2007).
Currently, following the recognition of the aetiological
relationship between MALT lymphomas and H. pylori (Woth-
erspoon et al, 1991) and the subsequent demonstration of
lymphoma regression following successful eradication with
antibiotics of the micro organism (Wotherspoon et al, 1993;
Bayerdorffer et al, 1995; Roggero et al, 1995), the diagnosis is
usually made by endoscopic biopsy. A non-surgical, stomach-
conserving approach (i.e. eradication of H. pylori as the sole
initial treatment) is widely employed in the treatment.
However, no evidence-based treatment guidelines exist for
the management of patients after antibiotic failure and in
particular whether there is a role for further adjuvant therapy,
such as chemotherapy (Yoon et al, 2004; Ferrucci & Zucca,
2007). Some data on the efﬁcacy of chlorambucil as ﬁrst line
treatment in gastric MALT lymphomas has been reported in
the older literature. One non-randomised trial by Hammel
et al (1995) assessed the activity of cyclophosphamide and
chlorambucil in low-grade MALT lymphomas, demonstrating
5-year event-free survival and overall survival of 50% and 75%
respectively.
The International Extranodal Lymphoma Study Group
(IELSG) and United Kingdom Lymphoma Group (UKLG),
together with the Groupe d’Etude des Lymphomes de l’Adulte
(GELA), conducted a trial to ascertain whether the addition of
chlorambucil is of beneﬁt after anti-H. pylori therapy in
patients with non-progressive gastric MALT lymphomas. No
other randomised trials have been performed in gastric MALT
lymphomas before.
Patients and methods
Patient selection
Patients were eligible for registration if aged 18 years or over
with non-resected, partially or completely resected low-grade
gastric lymphomas, stage I according to the Blackledge-
modiﬁed Lugano staging system (Rohatiner et al, 1994), and
with or without histological evidence of H. pylori infection. All
cases were subsequently reviewed centrally. Ethical committee
approval was obtained for the study and all patients gave
informed consent.
Trial design
Eligible patients were registered and treated with antibiotics
according to local practices for H. pylori infection. Endoscopies
were performed 2–3 months after treatment to assess eradica-
tion of H. pylori. Conﬁrmation of successful eradication of
H. pylori was according to local practice as there is usually a
good agreement on the value of histological assessment of
H. pylori eradication. The assessment of tumour response
would be performed up to 4–6 months after the organism had
been eradicated.
Patients in whom H. pylori was successfully eradicated with
complete regression of lymphoma were eligible for randomi-
sation. Patients in whom H. pylori was successfully eradicated
with partial regression or stabilisation of lymphoma might be
randomised according to the clinician’s discretion.
Patients were randomised to either observation or chlor-
ambucil. Chlorambucil was chosen because, at the time the
study was designed, single-agent chlorambucil was the
accepted standard treatment for low-grade Non-Hodgkin
lymphomas in most European countries. The drug was given
6 mg/m
2 daily orally for 14 d, repeated every 28 d for six
cycles.
Pathology review
All gastric biopsies of patients registered were reviewed
independently by a panel of pathologists. Histological diagno-
sis of gastric MALT lymphomas was made according to the
criteria deﬁned by Isaacson and Wright (1983) with the
presence of an extrafollicular or perifollicular diffuse inﬁltrate
of centrocyte-like cells in the lamina propria with lymphoepi-
thelial lesions. Immunohistochemistry was performed on
parafﬁn sections using antibodies against CD20, CD3 and
cytokeratin where appropriate. Presence of H. pylori was
assessed on modiﬁed Giemsa stained sections and, in a
proportion of cases, by culture.
Investigations and response assessment
Investigations prior to randomisation and during follow-up
included history, physical examination and routine blood
tests. Assessment of tumour response was not made until
4–6 months after eradication of H. pylori. Endoscopy was
performed every six months for the ﬁrst 2 years then annually
or if there was a recurrence of symptoms. Tumour response
was assessed at each post treatment endoscopy with at least
eight biopsies. Histological assessment of lymphoma response
was made using the scoring system deﬁned by Wotherspoon
et al (1993). A complete remission (CR) was deﬁned as a
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Score (WS) £ 2; a partial remission (PR) was for a patient with
endoscopic normalization and a WS > 2; a patient with
endoscopic stable disease (SD) and WS > 2 was deﬁned as
SD; and patients with extension of the endoscopic lesions and
WS > 2 were considered progressive disease (PD). After a CR,
disease relapse was deﬁned if a patient had any disease
occurred; after a PR or SD, disease progression was deﬁned if
the disease got worse.
Treatment on relapse or progression
Relapse or progression was conﬁrmed histologically where
possible and the site of relapse documented. It was recom-
mended that the patient be restaged. If H. pylori infection was
present, further antibiotics were given. If a CR was then
obtained, a further period of observation was undertaken. For
patients who failed to achieve CR after further antibiotics, an
incomplete response was treated according to local practices
(chlorambucilwasrecommended)intheobservationarm.Inthe
chlorambucil arm, an incomplete response was treated with
furthercytotoxictreatment.Thechoicewaslefttothejudgement
of the clinician. Recommended options included less aggressive
chemotherapy, such as further chlorambucil, and more aggres-
sive regimens, such as CHOP (cyclophosphamide, doxorubicin,
prednisone, vincristine). The choice of local resection or
radiation therapy was also at the discretion of the clinician.
Statistical considerations
The primary outcome measure was recurrence/progression
rate; secondary outcome measures were recurrence/progres-
sion-free survival and overall survival. The anticipated endo-
scopic relapse rate in patients treated for H. pylori infection
without chlorambucil was 40% at 5 years, meaning a total of
173 patients would be required to demonstrate a reduction to
20% with 5% signiﬁcance level and 80% power. Planned
recruitment was therefore 200 patients randomised.
Recurrence/progression rate was estimated using the Kap-
lan–Meier approach; patients who died from causes other than
lymphoma were censored at the time of death. Recurrence/
progression-free survival was deﬁned from the date of
randomisation to the date of the ﬁrst recurrence/progression
or date of death from any cause whichever occurred ﬁrst; at the
time of the analysis survivors without disease recurrence/
progression were censored at the date of last follow-up. Overall
survival was deﬁned from the date of randomisation to the
date of death from any cause; at the time of the analysis
survivors were censored at the date they were last known to be
alive. The log-rank test was applied to compare the Kaplan–
Meier curves for recurrence-free survival and overall survival.
The relative beneﬁts of chlorambucil on recurrence/progres-
sion and overall survival were assessed in an exploratory
manner in the subgroup deﬁned by the initial response after
antibiotics before randomisation.
All analyses were done on an intention-to-treat basis. All P
values were two-sided and were considered signiﬁcant when
<0Æ05. Analyses were performed using sas 9.10.
Results
Patients
Between March 1995 and March 2001, a total of 231 patients
(132 IELSG, 64 UKLG, 35 GELA) were registered
internationally at the UK Lymphoma Trials ofﬁce (UK LTO)
and GELA. One hundred and ten of these patients were
subsequently randomised (56 to chlorambucil and 54 to
observation) (Fig 1). The trial was stopped early due to slow
recruitment inﬂuenced, it was thought, by increasing
awareness of the long-term successes possible with H. pylori
eradication.
The baseline characteristics of patients registered are sum-
marised in Table I. There were 231 patients with median age of
62 years of whom 51% were male. The patients had an Eastern
Cooperative Oncology Group (ECOG) performance score (PS)
of 0–1 in 98% of cases and 97% were stage I. B symptoms were
present in 8%. H. pylori infection was present in 89% and
resection had been undertaken in 7%. Other symptoms at
registration included nausea/vomiting (10%), pain/dyspepsia
(55%) and anorexia (10%). Associated autoimmune disease
was present in 7% (Hashimoto thyroiditis 2%, rheumatoid
arthritis 1%, other 4%), and 8% had a second tumour. The
most common sites of lymphoma were antrum only (41%),
corpus only (24%) and antrum + corpus (16%). There were
3% patients who had the endoscopic appearance of a normal
mucosa, while 28% had features of chronic gastritis/hypera-
emia, 3% had erosions, 38% had an ulcer, and 31% had other
endoscopic appearances or combinations of two or three of the
previous ﬁndings.
Of the 231 registered patients, 97% had H. pylori eradicated
after antibiotics and 59% had macroscopically normal mucosa.
The tumour response rates were CR in 46%, PR in 20%, SD in
30% and recurrence/progression in 8% (Table II). One
hundred and ten patients were randomised (56 chlorambucil
and 54 observation) with 63 patients in CR, 23 with PR, 15
with SD and nine unknown (Table II). The baseline charac-
teristics of randomised patients were similar to those of all
patients at initial registration and were balanced between
randomisation arms (Table III). The subsequent analyses
focused on randomised patients only.
Treatment received
There was 98% protocol treatment compliance. One patient in
the chlorambucil arm did not have the allocated treatment due
to the patient’s refusal of chemotherapy. In the observation
arm, one patient had chlorambucil 10 months after randomi-
sation without disease recurrence. Chlorambucil was given for
a median of 29 weeks (range 3–39).
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low-grade Non-Hodgkin lymphomas in most European
countries at the time the study was designed, with a well-
known safety proﬁle and high tolerability, toxicity data were
not collected in detail. In fact, no cases of severe treatment-
related toxicity were reported.
Outcome measures
At the time of analysis, the median (range) follow-up from
randomisation was 58 (4–115) months. The events of recur-
rence/progression or death are summarised in Table IV.
A total of 17 patients had disease recurrence/progression (10
in the observation arm and seven in the chlorambucil arm).
The 5-year recurrence/progression rates from randomisation
were 21% in the observation arm and 11% in the chlorambucil
arm, with a difference of 10% and 95% conﬁdence interval
(CI) of the difference being )9% to 29%, P =0 Æ15. Figure 2
shows the cumulative incidence rate.
Twenty-two patients (11 in each arm) had disease recur-
rence/progression or died. No difference was detected between
the two treatment arms [Hazard Ratio (HR) = 0Æ96, 95%
CI = 0Æ41–2Æ2, P =0 Æ91]. The 5-year recurrence/progression-
free rate from of randomisation for all randomised patients
was 79% (Fig 3).
There were six deaths in total at the time of analysis. Two
occurred in the observation arm and four in the chlorambucil
arm. The two deaths in the observation arm were due to a
myocardial infarction in a patient who had disease progression
before death in one patient and to a small cell lung cancer in
the other. The four deaths in the chlorambucil arm were due to
malignant melanoma (1), cardiac failure (2) and unknown
(not lymphoma related) (1). There was no survival difference
between the two arms (HR = 1Æ93, 95% CI = 0Æ39–9Æ58,
P =0 Æ42). The 5-year overall survival rate from randomisation
for all randomised patients was 93% (Fig 4).
Fig 1. Trial proﬁle.
Table I. Patients characteristics at registration.
Total n = 231 (%)
Group
GELA 36 (15)
IELSG 132 (57)
UKLG 64 (28)
Age (years)
£60 104 (45)
60–65 31 (13)
>65 96 (42)
Median (range) 62 (20–86)
Male 118 (51)
Site of gastric lymphoma
Antrum 90 (41)
Corpus 53 (24)
Fundus 20 (9)
Stump 4 (2)
Other 6 (3)
Antrum + corpus 26 (12)
Antrum + fundus 5 (2)
Antrum + other 2 (1)
Antrum + corpus + fundus 9 (4)
Corpus + fundus 5 (2)
Corpus + fundus + other 1 (<1)
Fundus + stump 1 (<1)
Unknown 9
Macroscopic ﬁnding: normal mucosa
No 214 (97)
Yes 7 (3)
Unknown 10
H. Pylori infection
No 26 (11)
Yes 202 (89)
Unknown 3
Previous resection
No 212 (93)
Partial 9 (4)
Complete 6 (3)
Vagotomy 1 (0)
Unknown 3
Stage
I 214 (97)
II1 6 (3)
Unknown 11
ECOG performance status
0 163 (76)
1 46 (21)
2 5 (2)
Unknown 17
B symptoms
No 208 (92)
Yes 17 (8)
Unknown 6
Immune disorder
No 204 (90)
Yes 22 (10)
Unknown 5
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effective than observation in different responses to antibiotics
at randomisation for either recurrence/progression or overall
survival.
Discussion
Localised gastric MALT lymphoma is an indolent disease with
characteristic features. Despite abundant literature on histo-
logical, clinical and biological features of MALT lymphoma,
results of controlled trials to deﬁne optimal therapy are
limited. Insufﬁcient staging and outdated histological classiﬁ-
cations are a major problem of the older reports. Even more
recent studies often refer to retrospective series of patients not
uniformly staged and treated (Ferrucci & Zucca, 2007).
Moreover, the interpretation of residual lymphoid inﬁltrate
in post-treatment gastric biopsies is often difﬁcult and there is
a lack of uniform reproducible criteria in the literature for the
deﬁnition of histological remission (Ferrucci & Zucca, 2007).
The Wotherspoon Score (Wotherspoon et al, 1993) we used is
very useful to express the degree of conﬁdence in the MALT
lymphoma diagnosis on small gastric biopsies, it was initially
proposed as a simple method to deﬁne the histological
responses following antibiotic treatment, however, it is some-
times difﬁcult to apply in the evaluation of the response to
therapy. Thus, other criteria have been proposed with the aim
of providing clinically relevant information to the clinician
(Copie-Bergman & Wotherspoon, 2008). These differences in
evaluation criteria explain the wide range of the repor-
ted remission rates in the literature (Ferrucci & Zucca, 2007).
Our study conﬁrmed that H. pylori eradication results in
regression of lymphoma in the majority of cases (65% CR/PR,
29% SD and 5% PD). Addition of ‘adjuvant’ chlorambucil
conferred no beneﬁt. In the randomised study 5-year recur-
rence/progression-free survival was similar (77% versus 81%)
for observed and chlorambucil treated patients. Overall
survival was also similar (94% versus 92% respectively). In
none of the randomised patients on the trial was lymphoma
the cause of death and there have been no cases of transfor-
mation from low- to high-grade lymphoma. The median
follow-up for patients on trial is still only 58 (range 4–115)
months; however over one half of the lymphoma relapses (10
in 17 cases) occurred in the ﬁrst year of follow-up.
Of the original 231 patients registered only 110 (well short of
the original target) went on to be randomised. Eleven patients
were not randomised due to disease progression and 44 due to
inadequate response to antibiotics. Other cases were not
randomised despite being eligible – sometimes because of
patient refusal, more often clinician reluctance (as initiation of
the study preceded the recognition of the excellent prognosis
of antibiotic-treated gastric MALT lymphoma).
Indeed, there has been increasing evidence over the years
that H. pylori eradication as single therapy results in excellent
disease control in early-stage gastric MALT lymphoma (Chini
et al, 2007; Fischbach et al, 2007). We are aware that current
study was not powered to detect a small difference between
two groups. However, it may not be possible in practice to
conduct a larger randomised study with time to event outcome
measures for this group of patients due to patient population
and excellent disease control. In addition, the relapse/
progression rate (including in the observational arm) was less
than had been anticipated when the trial was designed – this
may reﬂect the fact that the analysis includes only randomised
patients who had not progressed after anti-Helicobacter
therapy, by deﬁnition a better prognostic group. Nevertheless,
this is the only randomised study in gastric MALT that has
been conducted.
Table I. (Continued).
Total n = 231 (%)
Second tumour
No 208 (92)
Epithelial 15 (7)
Haematological 2 (1)
Unknown 6
GELA, Groupe d’Etude des Lymphomes de l’Adulte; IELSG, Interna-
tional Extranodal Lymphoma Study Group; UKLG, United Kingdom
Lymphoma Group; ECOG, Eastern Cooperative Oncology Group.
Table II. Response after antibiotics.
Total (%)
Not
randomised
Randomised
Observation Chlorambucil Total
Total 231 121 54 56 110
CR 92 (46) 29 31 32 63
PR 40 (20) 17 11 12 23
SD 59 (29) 44 7 8 15
PD 8 (4) 8 0 0 0
H. pylori eradication
failure
3 (1) 3 0 0 0
Unknown 29 20 5 4 9
CR, complete remission; PR, partial remission; SD, stable disease/no change; PD, progressive
disease.
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2002) 120 patients were followed up endoscopically after anti-
Helicobacter therapy; 81% achieved CR, 9% PR and 10% were
non-responders. In those with complete remission there were
nine recurrences, none with local high-grade transformation.
With a median follow-up of 4 years, two of the non-
responders died of their lymphoma. The others had surgery
and/or chemotherapy and in half the lymphoma had become
histologically high-grade. With PR, patients had surgery,
chemotherapy or, in two cases, surveillance only; there was
Table III. Patients characteristics at registration for randomised pa-
tients.
Total
Observation Chlorambucil
n = 54 (%) n = 56 (%)
Group
GELA 11 11
IELSG 34 30
UKLG 9 15
Age (years)
£60 21 (39) 30 (54)
60–65 10 (19) 9 (16)
>65 23 (43) 17 (30)
Median (range) 63 (28–86) 58 (27–86)
Male 28 (52) 32 (57)
Site of gastric lymphoma
Antrum 23 (43) 18 (34)
Corpus 10 (19) 18 (34)
Fundus 9 (17) 5 (9)
Stump 0 (0) 1 (2)
Other 0 (0) 1 (2)
Antrum + corpus 6 (11) 6 (11)
Antrum + fundus 1 (2) 2 (4)
Antrum + other 2 (4) 0 (0)
Antrum + corpus + fundus 2 (4) 2 (4)
Corpus + fundus 1 (2) 0 (0)
Unknown 0 3
Macroscopic ﬁnding: normal mucosa
No 51 (96) 54 (100)
Yes 2 (4) 0
Unknown 1 2
H. Pylori infection
No 5 (9) 3 (5)
Yes 49 (91) 53 (95)
Previous resection
No 50 (93) 50 (91)
Partial 1 (2) 4 (7)
Complete 3 (6) 1 (2)
Unknown 0 1
Stage
I 52 (98) 53 (100)
II1 1 (2) 0 (0)
Unknown 1 3
ECOG performance status
0 43 (83) 36 (68)
1 7 (13) 15 (28)
2 2 (4) 2 (4)
Unknown 2 3
B symptoms
No 54 (100) 49 (91)
Yes 0 (0) 5 (9)
Unknown 0 2
Immune disorder
No 47 (87) 52 (95)
Yes 7 (13) 3 (5)
Unknown 0 1
Table III. (Continued).
Total
Observation Chlorambucil
n = 54 (%) n = 56 (%)
Second tumour
No 50 (93) 48 (89)
Epithelia 4 (7) 4 (7)
Haematological 0 (0) 2 (4)
Unknown 0 2
GELA, Groupe d’Etude des Lymphomes de l’Adulte; IELSG,
International Extranodal Lymphoma Study Group; UKLG, United
Kingdom Lymphoma Group; ECOG, Eastern Cooperative Oncology
Group.
Table IV. Summary events for randomised patients.
Total
Observation Chlorambucil
n = 54 (%) n = 56 (%)
Alive without recurrence/progression 43 (80) 45 (80)
Alive with recurrence/progression 9 (17) 7 (13)
Dead without recurrence/progression 1 (2) 4 (7)
Recurrence/progression and dead 1 (2) 0 (0)
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Fig 2. Cumulative incidence rate of recurrence/progression.
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comparable to ours where reported follow-up is only for those
randomised to either observation or chlorambucil after
attaining histological response or stable disease following
H. pylori eradication.
We have previously reported the clinical and molecular
follow-up of these patients following anti-Helicobacter therapy
(Bertoni et al, 2002). Whilst more than one half of patients
with MALT lymphoma failed to achieve sustained molecular
remission after treatment, this does not appear to be associated
with histological relapse, though only long-term follow-up can
conﬁrm this (Bertoni et al, 2002). Meanwhile, medium term
follow-up of those patients proceeding on the randomised
study conﬁrmed the excellent prognosis of those who respond
to such therapy. We can also conclude that chlorambucil
chemotherapy makes no difference to the recurrence/progres-
sion of lymphoma. This cannot of course be extrapolated to
infer that all chemotherapy will make no difference, however,
the gains in terms of increased survival and quality of life
would have to be substantial to make the intervention
worthwhile. On the other hand, rituximab may be worthy of
evaluation in the adjuvant situation (Martinelli et al, 2005).
Only 10% of patients in this randomised study had gastric
resection; none subsequently had further surgery. This
conﬁrms current practise where the role for surgery in the
treatment for gastric lymphoma is declining (Yoon et al, 2004;
Ferrucci & Zucca, 2007).
Various markers have been suggested as predictive of
response to anti-Helicobacter therapy, for example stage of
disease, depth of inﬁltration and t(11:18) translocation
(Ruskone-Fourmestraux et al, 2001; Wundisch et al, 2005).
Recently the presence of t(11:18) has been shown to be
associated with resistance to oral alkylating agents (Levy et al,
2005) but not to rituximab (Martinelli et al, 2005). At the time
of the start of this trial the association between the translo-
cation and chlorambucil was unknown and this has yet to be
analysed in our cohort. Nevertheless, as the translocation is
associated with a lack of response to antibiotics (Liu et al,
2002) it seems unlikely that its presence may have biased the
results of the study because most patients (86/110) had a clear
histological regression of the lymphoma at the time of
randomisation, with well balanced overall (78% in both arms)
and complete (67% in both arms) remission rates.
Based on these early results we can conclude that there is
no clear evidence that single agent chemotherapy using
chlorambucil contributes to the prevention of recurrence/
progression in localised gastric MALT lymphoma after
successful treatment with antibiotics. This might be due to
the very favourable outcome of the patients in the observa-
tion group. This could not be expected at the time the study
was designed but nowadays there is increasing evidence that
antibiotic treatment allows an excellent long-term disease
control and after successful eradication of the micro organ-
ism a ‘watch and wait’ policy with regular endoscopies and
biopsies appears to be safe even in patients with evidence of
residuals of MALT lymphoma (Chini et al, 2007; Fischbach
et al, 2007). On the other hand, this good long-term outcome
of many patients with less than complete lymphoma remis-
sion should minimize the possible selection bias related to the
enrolment in this study of PR and SD patients according to
investigator discretion.
Longer follow-up will allow further assessment of time to
recurrence/progression and incidence of transformation to
high-grade disease. Clinical practice has moved away from
surgery over the past 10 years or so (Yoon et al, 2004; Bertoni
& Zucca, 2005) and this and other studies (Bayerdorffer et al,
1995; Roggero et al, 1995; Pinotti et al, 1997; Koch et al, 2005;
Wundisch et al, 2005) have inﬂuenced this change.
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